Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients

Multiple Sclerosis and Related Disorders(2022)10.1016/j.msard.2022.103729Source: DataRank Database

Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients is a research paper published in Multiple Sclerosis and Related Disorders (2022). On theSindex it has a DataRank of 0. It has been cited 32 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access32 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 3.09)OA: hybridTopics (52)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Frederik Novak,Anna Christine Nilsson ORCID,Christian Nielsen ORCID,Dorte Kinggaard Holm ORCID,Kamilla Østergaard

Live enrichment

PubMed:35334278 PMC:PMC8898195 OpenAlex:https://openalex.org/W4220825786

NIAID NIH HHS

Grant: R01 AI131624

National Institutes of Health

Merck

Alexion Pharmaceuticals

Roche

Teva Pharmaceutical Industries

National Multiple Sclerosis Society

Novartis

Biogen

FWCI

3.09

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.msard.2022.103729

publisherhttps://doi.org/10.1016/j.msard.2022.103729

publisherhttps://api.elsevier.com/content/article/PII:S2211034822002449?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211034822002449?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35334278

Fields of Study

SARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesAnimal Virus Infections StudiesAntibodies, ViralAntigens, CD20BNT162 VaccineCD8-Positive T-LymphocytesCOVID-19COVID-19 VaccinesHumansImmunity, CellularLeukocytes, MononuclearLongitudinal StudiesMultiple SclerosisProspective StudiesRNA, MessengerSARS-CoV-2Vaccination

MeSH Terms

COVID-19SARS-CoV-2COVID-19 VaccinesBNT162 VaccineAntibodies, ViralHumansImmunity, CellularLeukocytes, MononuclearLongitudinal StudiesMultiple SclerosisProspective StudiesRNA, MessengerVaccinationCD8-Positive T-LymphocytesAntigens, CD20

Keywords

MedicineMultiple sclerosisImmune systemImmunologyCD20VaccinationVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyCoronavirus disease 2019 (COVID-19)PathologyDiseaseAntibody responseAnti-cd20OcrelizumabMrna VaccineBooster VaccineSars-cov-2Bnt162b2

Sustainable Development Goals

SDG 0: Good health and well-being